NCT00257621已完成2 期
A Pilot, Phase II, Open-label, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GW640385 When Administered With Ritonavir in Combination With NRTIs for 48 Weeks in HIV-1 Infected Adults
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 10
- 主要终点
- Percentage of subjects with plasma HIV-1 RNA <400 copies/ml. Incidence of serious adverse events, rash and thyroid function abnormalities. GW640385 PK parameters.
研究概览
简要总结
This is a proof of concept (POC) single arm study of GW640385, a protease inhibitor, in combination with RTV and 2 or more nucleoside reverse transcriptase inhibitors (NRTI) backbone. This study has a 48 week duration and is open to both treatment naive and experienced patients who are HIV positive. There are 3 intensive pharmacokinetic (PK) visits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Percentage of subjects with plasma HIV-1 RNA <400 copies/ml. Incidence of serious adverse events, rash and thyroid function abnormalities. GW640385 PK parameters.
时间窗: throughout the study
次要结局
- Changes over time in HIV-1 viral load and CD4+ cell counts. Incidence of adverse events and laboratory abnormalities. GW640385 and RTV PK parameters. Development of resistance in subjects with virologic failure.(throughout the study)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
2 期
Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung TransplantationLung Transplant RejectionNCT02474927John F. McDyer, MD22
Unknown
2 期
Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)MetastasisHepatocellular CarcinomaNCT02311205Asan Medical Center55
Unknown
2 期
Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic CancerMetastatic Pancreatic CancerNCT03929094Fudan University120
招募中
2 期
Combination of TURP and Standard Systemic Therapy for MPCaMetastatic Prostate CancerNCT06655259Fudan University200
终止
2 期
Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian CancerOvarian NeoplasmsNCT03955471Tesaro, Inc.41